Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.
Beteiligte Einrichtungen
Abstract
XIAP (X-linked inhibitor of apoptosis protein) is an inhibitor of caspases 3 and 9 that is overexpressed in acute myeloid leukemia (AML) and may contribute to chemoresistance. We report an open-label randomized phase II trial of reinduction chemotherapy with and without the XIAP antisense oligonucleotide AEG35156 in patients with AML who did not achieve remission with initial induction chemotherapy.
Bibliografische Daten
| Originalsprache | Englisch |
|---|---|
| Aufsatznummer | 5 |
| ISSN | 2152-2650 |
| Status | Veröffentlicht - 2011 |
| pubmed | 21729686 |
|---|
